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agnetic Resonance Imaging
nd Troponin Elevation
ollowing Percutaneous
oronary Intervention
ew Insights Into Myocyte Necrosis
nd Scar Formation*
aul Schoenhagen, MD,† Harvey D. White, DSC‡
leveland, Ohio; and Auckland, New Zealand
erum biomarker evidence of myocyte necrosis is frequently
ound after percutaneous coronary intervention (PCI). About
0% of patients develop elevated levels of creatine kinase-
yocardial band (CK-MB) (1,2) and up to 48% of patients
evelop elevated troponin levels following PCI (2–9). Several
echanisms related to procedural complications such as side
ranch occlusion, dissection, and disruption of collateral flow
ave been proposed for these elevations. The concept of plaque
mbolization at the time of balloon inflation or stent deploy-
ent leading to myocardial necrosis and scar formation has
een supported by observations with magnetic resonance
maging (MRI) and late gadolinium enhancement (LGE)
scar” imaging after PCI (10). These data show an association
etween post-PCI elevations of troponin I with MRI-
etectable scar formation.
See page 950
Following stenting, LGE may occur at the site of stent
eployment and distally in the treated coronary artery (11).
ntravascular ultrasound has shown a correlation between
hanges in plaque volume before and after PCI and the mass
f distal hyperenhancement, but not with hyperenhance-
ent at the site of stenting. Thus providing indirect
vidence that plaque embolization has occurred.
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uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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een shown to be related to abnormal tissue perfusion (12)
ndependent of the presence of thrombus, epicardial flow, or
haracteristics of the coronary artery stenosis undergoing
CI. Elevated biomarker levels are also associated with
igher atheromatous plaque burden (13).
The universal definition of myocardial infarction (MI)
esignates biomarker increase (with troponin preferred)
rom a normal baseline to a level 3 times the 99th percentile
s PCI-related MI (Type 4a) (14). The importance of the
ssociation between elevated biomarker levels after PCI and
rognosis continues to be debated. Several studies have
hown that the elevation of troponin levels after PCI is
trongly associated with the composite of death and MI
2,5). However, the associations have usually been with early
utcomes (hospital or 90 days) and not with later follow-up
4). A further important consideration is the level of the
levation with 1 study (6) showing that only troponin levels
5 times the upper limit of normal were prognostically
mportant. In some studies (7), prognosis did not seem to be
nfluenced if baseline pre-PCI levels were not elevated (15).
recent meta-analysis (9) of 15 studies showed that
atients with normal baseline and any elevation of post-PCI
roponin levels had increased risk of major adverse cardiac
vents (death, MI, repeat PCI, and coronary artery bypass
raft [CABG]) when compared with those patients without
roponin elevation at an average follow-up of 17.7 months.
or patients fulfilling the universal definition of type 4a MI
14), there was a further increased risk: odds ratio: 2.5 (95%
onfidence interval 1.26 to 4.00). Patients with elevation of
roponin 3 times the upper limit of normal did not have
worse prognosis during follow-up. In general, serum
iomarkers do not allow the characterization of localization
nd distribution of the underlying pathological process.
This limitation can be overcome by correlation with
maging modalities, as exemplified by the study of Locca et
l. (16) in the current issue of JACC: Cardiovascular Inter-
entions, which compared elevation of troponin I levels
easured by (Beckman Access 2 [Beckman Coulter, Brea,
alifornia]) analyzer, which is clinically useful but not
uideline compliant (17) to MRI and LGE after PCI in 45
atients. New LGE occurred in 33.3% of patients. The scars
ere mostly small including 1.5% of left ventricular mass
n 14 of 15 patients and had no effect on ejection fraction.
he site of the infarction was distal in 53% and proximal in
7% of patients. Interestingly, post–stent dilation, probably
y causing more plaque embolization, was the only factor
ssociated with LGE. Elevation of biomarkers beyond 3
imes the upper limit of normal occurred with CK-MB in
1% of patients and with troponin I in 47% of patients.
orrelation of LGE with elevation of biomarkers was
oderate, occurring in 40% of patients with elevation of
reatine kinase-myocardial band and 43% of patients with
levation of troponin I.
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960The underlying mechanism of MRI myocardial tissue
nhancement with nonspecific extracellular contrast agents
uch as gadolinium is the increased distribution volume for
hese molecules within the infarct region with delayed
ashout in comparison to the normal myocardium (18).
elayed contrast-enhanced MRI is well validated in the
dentification of chronic myocardial scar (19,20). It has
ufficient spatial resolution to differentiate patterns of trans-
ural or subendocardial necrosis in the distribution of
bstructed vessels (20,21), and more diffuse, patchy
atterns of necrosis related to distal embolization (22). In
everal single-center trials, the prognostic impact of
RI-detected scar has been demonstrated in different
atient populations (23–25).
It is important to consider issues related to scar size with
GE imaging. The minimal detectable scar volume de-
ends on the spatial resolution of the MRI sequence. In the
urrent study (16), similar to most other studies, spatial
esolution was 1.4 1.7 mm in plane with slice thickness of
mm and a 2-mm gap. Therefore, the minimal resolvable
olume from a theoretical standpoint would be about 0.02
l. However, practically, a bigger volume (a few times the
inimal resolvable volume) is necessary to differentiate scar
rom noise. In the current study (16), the mean scar size was
.83 g (about 40 times the minimal resolvable volume),
quivalent to 0.53% of the size of the normal left ventricular
yocardium. This is relatively small in comparison to other
tudies after intervention (2 g) (22), PCI and CABG (5 g)
26), CABG (4.4 g) (27), and reperfused acute MI (20.6 g)
28). The timing between myocardial injury and LGE
maging is important, because serial MRI studies performed
uring the acute phase of MI have shown that the size of
elayed gadolinium enhancement may significantly change
mmediately after reperfusion, secondary to resolution of
nterstitial edema in reversibly injured myocardium within
he peri-infarction zone (28–31).
Previous studies describe LGE imaging for the identifi-
ation, characterization and quantification of periprocedural
yocardial necrosis after PCI (22,26,30) and coronary
ypass surgery (CABG) (27). In these studies, the mass of
nfarcted tissue correlated with elevation of biochemical
arkers of myocardial damage (32). In contrast, the current
Table 1. Comparison of Troponins With MRI for Detecting Myocyte Necros
Contemporary Troponin Assays
Cutoff: normal vs. pathologic Well-deﬁned
Sensitivity/spatial resolution Very sensitive, no localization
Time pattern of rise and fall Well known but limitations, e.g., delayed response
from nonreperfused myocardium
Method standardization High
Relation with prognosis Controversial (2,4,5–8,15)
Fulﬁlls universal deﬁnition of MI FewMImyocardial infarction; MRImagnetic resonance imaging.ata by Locca et al. (16) demonstrate that in many patients
ith elevated troponin I, LGE imaging could not identify
vidence of scar. The investigators raise the question as to
hether current cutoff levels of biomarkers are too sensitive,
eading to overdiagnosis of post-PCI MI. An alternative
xplanation in the context of uncomplicated PCI would be
mall and patchy myocardial necrosis related to distal
mbolization of plaque (11,22,33). False negative results
ith LGE imaging would be expected in patients with
ultiple small areas of necrosis, if individual scar area were
maller than the spatial limitation of the MRI sequence.
Animal and post-mortem studies may provide further
nsights. However, more important will be clinical trials
omparing quantitative extent of biomarker elevation and
GE scar with clinically meaningful outcome. Small studies
how an independent predictive value of delayed LGE
maging in patients undergoing coronary revascularization,
ither PCI or CABG, during a median follow-up of 2.9
ears (26). However, long-term outcome data from well-
esigned, prospective, multicenter trials are lacking. In the
esign of such trials, it will be critical to consider the
nability of differentiating procedure-related versus pre-
xisting infarction, therefore requiring pre- and post-
perative MRI acquisitions. Strict standardization of image
cquisition and analysis, including contrast dose and thresh-
ld definition for identification of scar is vital (34–36). A
imitation of MRI is the contraindication in patients with
educed kidney function (glomerular filtration rate 30
l/min) because of concerns about nephrogenic systemic
brosis (37). Table 1 compares troponins, including the
ewer higher sensitivity troponins (38), with MRI for
etecting myocyte necrosis. Much of the data are evolving.
Future clinical trials, correlating clinical outcome with
oth biomarkers and comprehensive MRI imaging (LGE
nd T2-weighted), characterizing scar and the at-risk area
arly after infarction, respectively (31,39,40), will provide
mportant further insight into periprocedural necrosis.
owever, even if such data will eventually be available, it is
nrealistic to propose pre-and post-procedural LGE for
outine PCI. In the context of the current debate about
ealth care costs, it appears more realistic that such data will
alibrate levels of biomarker elevation to corresponding scar
her Sensitivity Troponin Assays MRI
lving (38) Evolving
remely sensitive, no localization Localization, but limited spatial resolution
lving Decrease of scar area during the ﬁrst week (28)
h Evolving
lving Evolving
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961ass and distribution and help define clinical biomarker
riteria for defining post-PCI MI.
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